Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

NCT03368170 is registered in ClinicalTrials.gov with Integrative Research Laboratories AB as lead sponsor.

NCT NCT03368170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03368170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Lead sponsor
Integrative Research Laboratories AB
Phase
Phase 2
Overall status
Completed
Start date
April 12, 2018
Completion date
June 12, 2019
Enrollment
75 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease